HOUSTON, Sept. 21, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced that its special purpose subsidiary, Argatroban Royalty Sub LLC ("Royalty Sub"), has refinanced $60 million in aggregate, original principal amount of non-convertible, non-recourse promissory notes (the "Original Notes") sold to institutional investors in February 2007. The Original Notes were secured by royalties paid from sales of Argatroban, a drug licensed by Encysive and sold by GlaxoSmithKline plc ("GSK"), for the treatment of heparin-induced thrombocytopenia, and by a pledge by Encysive of the stock of Royalty Sub.
In the refinancing announced today, Royalty Sub issued $68 million principal amount of new non-convertible, non-recourse promissory notes (the "New Notes") in exchange for the Original Notes and approximately $14.4 million in cash. Since February 2007, approximately $6.4 million of principal on the Original Notes had been redeemed. After fees and expenses and the payment of approximately $1.4 million in interest accrued on the Original Notes, Encysive netted $11.2 million from the issuance of the New Notes.
All interest and principal payments on the New Notes will be made solely from royalties and other payments payable under the license agreement between Encysive and GSK, all of which were transferred to Royalty Sub in February 2007. The New Notes are non-recourse and non-convertible and have not been guaranteed by Encysive.
The New Notes will bear interest at 18.5% per annum payable quarterly beginning September 30, 2007. If the Argatroban royalties received for any quarter exceed the interest payments and expenses due for that quarter, the excess will be applied to the repayment of principal of the New Notes until the New Notes have been paid in full. Any portion of the principal amount of the New Notes not repaid on or before the legal final maturity date of September 30, 2014 will be payable on that date. In addition, the New Notes may be redeemed at Encysive's option on any quarterly payment date, subject to the payment of a make-whole payment (if the redemption occurs on or before June 30, 2008) or a redemption premium (if repaid on any quarterly payment date between September 30, 2008 and June 30, 2010). On and after September 30, 2010, the New Notes may be redeemed without premium. Once the New Notes are repaid in full, Royalty Sub will retain all royalty and other payments due under the license agreement with GSK.
Encysive expects to use the proceeds of the New Notes for general corporate purposes, including the development of Encysive's products and to support sales and marketing of THELIN(r)(1) (sitaxentan sodium)(2) in the European Union. THELIN is commercially available in the United Kingdom, Germany, The Netherlands, Ireland and Spain and is expected to become available in additional EU countries during the remainder of 2007. THELIN is also approved in Canada and Australia.
The New Notes were offered and sold in a private placement pursuant to Section 4(2) of the Securities Act of 1933 ("Act"), as amended. The offer and sale of the New Notes was not and will not be registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration, and the New Notes may be offered, sold or transferred only to U.S. citizens who are qualified institutional buyers (as defined in the Act) or other institutional accredited investors. A more detailed explanation of the obligations of Encysive and Royalty Sub can be found in Encysive's Form 8-K, to be filed with the Securities and Exchange Commission in connection with this transaction.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com.
The Encysive Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=843
(1) THELIN is an EU registered trademark of Encysive Pharmaceuticals Inc.
(2) "Sitaxentan" sodium is the spelling recognized by the World Health Organization for Encysive Pharmaceuticals' sitaxsentan sodium.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are whether the royalty and other payments under the agreement between Encysive and GSK will generate sufficient revenues to repay the New Notes in accordance with the terms of the New Notes, particularly because we rely on GSK to market Argatroban; our estimate of the sufficiency of our existing capital resources, our ability to raise additional capital to fund cash requirements for future operations, our ability to manufacture and sell any products, potential drug candidates, their potential therapeutic effect, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate, and our ability to discover new drugs in the future, as well as more specific risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion.